NRC Health outlines path back to low-30s EBITDA margin while targeting $1M-$1.5M quarterly CapEx
NRC Health (NASDAQ:NRC) reported strong Q1 2026 sales and adjusted EBITDA performance, with total recurring contract value (TRCV) increasing 13% year-over-year to $152 million. The company is targeting a return to low-30s EBITDA margins and plans quarterly capital expenditures of $1 million to $1.5 million.
Tickers: $NRC
Topics: Earnings Call EBITDA Management Commentary Sales Performance TRCV